G Enblad

..The role of EBV in the development of HD, especially its relationship to the immunological response, remains unclear...

..Further studies are warranted in younger patients and patients with less advanced disease...

..We conclude that MIME induces remissions in a high proportion of patients with recurrent and refractory HD with acceptable toxicity. The remissions probably need consolidation, but the nature of this consolidation is still controversial...

..This could be explained by selection of patients from previous studies, or by differences in EBV-positivity in different geographical or ethnic populations of HD...

..Thus efforts to improve the chemotherapy regimen with individualized dosing did not change the outcome. Many patients experienced myelosuppression and opportunistic infections that may have contributed to the poor treatment results...

..Mast cells and eosinophils seem also to contribute to the fibrosis that is so characteristic for nodular sclerosis...

..In the absence of randomised trials the role of high-dose treatment for patients with follicular lymphoma is still not defined...

..The same patients had a higher ESR and tended to have a more advanced stage and bulky disease. There are no significant correlations with disease-free and overall survival, as the follow-up time is short, and prognosis favourable...

..The remissions are, however, generally of short duration and need consolidation. There was considerable toxicity therefore patients not suitable for ABMT preferably should be treated with less toxic salvage regimens...

..Secondly, we investigated if variables of prognostic importance could be detected...

....

..In conclusion, we suggest that bulky disease should be taken into account when treating patients with stage IIB HL...

..To study the effectiveness and tolerability of a dose-intensified treatment including rituximab for patients, not older than 65 yr, with high-risk aggressive B-cell lymphoma...

..Possible explanations could be selection of less malignant clones or a lymphoma controlled by the immune system. The mechanisms are, however, unknown but warrant further studies of the molecular biology in these and similar cases...

..Taken together, our results suggest that CCL5 produced by HRS cells is one mechanism by which mast cells can be attracted into the tumor tissue in HL...

..03 in both germinal centre (GC) and non-GC DLBCL. This supports the idea that the infiltration of mast cells is a reflection of the host inflammatory response and is related to a favourable outcome...

..The aim of this study was to explore if the expression of IL-9 correlates to the presence of these inflammatory cells in HL tumours...

..These results favour the trend to treat early and intermediate stages with a short course of chemotherapy followed by limited RT...

..Mast cells were detected in virtually every case and increasing numbers of mast cells correlated to nodular sclerosis histology (P = 0.008). Patients with higher mast cell infiltration had a worse relapse-free survival (P = 0.01)...

..In conclusion, mast cells are present in HD tumours and are the predominant CD30L-expressing cells. CD30L-CD30 interaction is a pathway by which mast cells may stimulate DNA synthesis in HRS cells...

..No severe side effects were observed during the antibody treatment. This case report is the first describing that HuMax-CD4 has antilymphoma activity in PTL and is an interesting drug to study further in patients with CD4+ PTL...

..A novel correlation between increased serum IL-9 levels, HL and clinical features is shown, suggesting that IL-9 is a candidate factor contributing to the development of HL...

..The aim of the study was to investigate the results of treatment of malignant parotid gland tumours at a single centre during a 56 year period, focusing on tumour control and survival...

..This cell line may become a useful tool to better understand the mechanisms responsible for development of secondary NHL in patients treated for HL...

..This study was undertaken to investigate whether RA displays a specific association with any of the DLBCL subtypes...

..Here we confirm the prognostic importance of determining the germinal- or nongerminal center phenotype in patients with DLBCL...

..This supports that a majority of RA-DLBCL are of non-GC origin, indicating a specific role for activated peripheral B cells in the pathogenesis of RA-DLBCL...

..These findings indicate that a reactive microenvironment has an impact on the outcome of chemotherapy in DLBCL...

..03), but they tended to be younger at diagnosis. The combined use of V(H)3-21/V(lambda)3-19 suggests a possible role for antigen(s) in the pathogenesis of these tumors and indicates that V(H)3-21(+) patients constitute a new MCL entity...

..It is thus possible that a biological relationship between the disorders may exist in addition to morphological overlaps, and the purpose with this review is to summarize the different relations between HL and NHL...

..002 and PFS, P=0.006). Neither MDM2 SNP309 nor the TP53 codon 72 polymorphism had an impact on age of onset or survival. Altogether, our data suggests that TP53 mutations are associated with poor outcome in GC-DLBCL patients...

..We therefore suggest that B-CLL cases with mutated V(H)3-21 genes may constitute an additional entity of B-CLL...

....

..030; FFS, 79% vs 52%, P = .028). We conclude that rituximab in combination with chemotherapy seems to eliminate the prognostic value of immunohistochemically defined GC- and non-GC phenotypes in DLBCL...

..Our aims were to evaluate the response to salvage treatment in relation to initial treatment and to evaluate prognostic factors at the time of relapse in an unselected population of relapsing patients with Hodgkin's lymphoma (HL)...

..We found a significant relation between the expression of p53 and EBV at diagnosis and relapse, indicating a clonal relationship. We were unable to find any specific staining pattern of p53 or Rb, affecting survival...

....

..For the first time, we show that ZAP70 is expressed in a higher percentage of tumor cells in the aggressive non-GC subgroup of DLBCL and that PKC-beta I and II are differently distributed in the two prognostic subgroups of de novo DLBCL...

....

....

..Multiple numerical and structural abnormalities were identified in DEV and HDLM-2, as well as in L-540. Refined composed karyotypes are suggested for the cell lines studied, to be used as references for further studies of lymphoma...

..These diseases include Hodgkin lymphoma, atopic dermatitis, and psoriasis...